Carmot’s IPO Filing Makes Case for Bias in Drugging Key Obesity, Diabetes Targets

A VPN is an essential component of IT security, whether you’re just starting a business or are already up and running. Most business interactions and transactions happen online and VPN

Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.

Leave a Replay

Sign up for our Newsletter

Contact Us